MARKET

PTGX

PTGX

Protagonist Ther
NASDAQ
89.65
+2.32
+2.66%
After Hours: 89.00 -0.65 -0.73% 18:37 12/05 EST
OPEN
87.96
PREV CLOSE
87.33
HIGH
90.18
LOW
87.54
VOLUME
1.47M
TURNOVER
--
52 WEEK HIGH
93.25
52 WEEK LOW
33.70
MARKET CAP
5.60B
P/E (TTM)
142.01
1D
5D
1M
3M
1Y
5Y
1D
Protagonist, Takeda present longer-term data at ASH 2025 on rusfertide
TipRanks · 7h ago
Protagonist And Takeda Report 52-Week Rusfertide Data In Polycythemia Vera
NASDAQ · 1d ago
Takeda Reports 52-Week Phase 3 Data Showing Rusfertide Maintains Hematocrit Control in Polycythemia Vera
Reuters · 1d ago
Weekly Report: what happened at PTGX last week (1124-1128)?
Weekly Report · 6d ago
Protagonist (PTGX) Earnings Call Transcript
NASDAQ · 11/27 22:41
Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3
Seeking Alpha · 11/27 12:20
Protagonist Therapeutics Reaches Analyst Target Price
NASDAQ · 11/26 11:57
Weekly Report: what happened at PTGX last week (1117-1121)?
Weekly Report · 11/24 10:22
More
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.

Webull offers Protagonist Therapeutics Inc stock information, including NASDAQ: PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTGX stock methods without spending real money on the virtual paper trading platform.